Serum neurofilament light chain and glial fibrillary acidic protein for predicting response to apheresis in steroid‐refractory multiple sclerosis relapses
European Journal of Neurology · 2024
DOI: 10.1111/ene.16323 ↗Kurz gefasst
Klinische Studie in der Zeitschrift European Journal of Neurology, 2024. Verfasst von Ioannis Vardakas und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, University of Ulm, Ulm, Germany. Hauptthemen laut MEDLINE: Blood Component Removal, Glial Fibrillary Acidic Protein, Neurofilament Proteins. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background and purpose The predictive value of serum neurofilament light chain (sNfL) and serum glial fibrillary acidic protein (sGFAP) for apheresis outcome in steroid‐refractory multiple sclerosis (MS) relapse has not yet been evaluated.
Methods
We used pre‐ and postapheresis serum samples from 38 participants of the IAPEMS trial ( clinicaltrials.gov : NCT02671682), which investigated the use of immunoadsorption versus plasma exchange for the treatment of steroid‐refractory MS attacks. Response to apheresis was classified based on improvement on (i) the Expanded Disability Status Scale (EDSS), (ii) the affected functional system scores (FSS) of the EDSS, or (iii) the visual acuity for patients with optic neuritis, 4 weeks postapheresis. sNFL and sGFAP were measured by single molecule arrays.
Results
Preprocedural sGFAP levels could discriminate between responders and nonresponders, determined by FSS improvement ( p = 0.017). In multivariate logistic regression analysis, younger age (odds ratio [OR] = 0.781, 95% confidence interval [CI] = 0.635–0.962, p = 0.020) and lower sGFAP levels (OR = 0.948, 95% CI = 0.903–0.995, p = 0.031) could predict response to apheresis in the overall cohort. We could observe a trend towards a favourable apheresis outcome with higher sNfL levels (OR = 1.413, 95% CI = 0.965–2.069, p = 0.076). Analysis of the sNfL‐to‐sGFAP ratio showed an OR of 1.924 (95% CI = 1.073–3.451, p = 0.028) for predicting apheresis response. The ratio showed a better predictive value than the individual parameters. Neither biomarker was affected by the number of steroid cycles preapheresis.
Conclusions
Lower sGFAP levels, a higher sNfL‐to‐sGFAP ratio, and younger age are associated with a favourable apheresis outcome.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, University of Ulm, Ulm, Germany.
- Institute for Epidemiology and Medical Biometry, University of Ulm, Ulm, Germany.
ORCID-Profile: Ioannis Vardakas, Johannes Dorst, Daniela Taranu
Zitieren
APA
Vardakas, I., Dorst, J., Huss, A., Mayer, B., Fangerau, T., Taranu, D., Tumani, H., & Senel, M. (2024). Serum neurofilament light chain and glial fibrillary acidic protein for predicting response to apheresis in steroid‐refractory multiple sclerosis relapses. European Journal of Neurology. https://doi.org/10.1111/ene.16323
Vancouver
Vardakas I, Dorst J, Huss A, Mayer B, Fangerau T, Taranu D, et al. Serum neurofilament light chain and glial fibrillary acidic protein for predicting response to apheresis in steroid‐refractory multiple sclerosis relapses. European Journal of Neurology. 2024. doi:10.1111/ene.16323
BibTeX
@article{Vardakas2024,
author = {Vardakas, Ioannis and Dorst, Johannes and Huss, André and Mayer, Benjamin and Fangerau, Tanja and Taranu, Daniela and Tumani, Hayrettin and Senel, Makbule},
title = {Serum neurofilament light chain and glial fibrillary acidic protein for predicting response to apheresis in steroid‐refractory multiple sclerosis relapses},
journal = {European Journal of Neurology},
year = {2024},
doi = {10.1111/ene.16323}
}
EUVIMED